SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Sepsis

SHREWSBURY, Mass. - March 25, 2025 - PRLog -- SignaBlok, Inc., (http://www.signablok.com/) a preclinical stage biotechnology company pioneering first-in-class, new mechanism-based peptide therapies for multiple diseases, today announced it will present positive preclinical data detailing therapeutic activity of its leading macrophage-restricted TREM-1 inhibitor in experimental sepsis, acute respiratory distress syndrome (ARDS), and pulmonary fibrosis (PF) at the RIS and ATS Conference in San Francisco, California from May 16-21, 2025.

Details on SignaBlok's upcoming 2025 RIS and ATS poster presentations are as follows:

• In septic animals, TREM-1 blockade by SignaBlok's first-in-class macrophage-restricted TREM-1 inhibitor protects from death with the level of protection not declining at delayed treatment times
• In rats, macrophage-restricted TREM-1 blockade significantly reduces lipopolysaccharide (LPS)-induced neutrophil accumulation in the lungs when injected after, but not before, LPS challenge
• Data highlight potential of SignaBlok's SCHOOL technology platform to support clinical development of TREM-1 drug with minimal risk of failure due to a new mechanism of action

Respiratory Innovation Summit:
Poster Title: Sepsis: Understanding Nature. Solving the Inflammation Puzzle. Saving Lives.
Presenter: Alexander B. Sigalov, Ph.D. (SignaBlok President and Principal Investigator)
Date / Time: Friday May 16, 2025 2 PM - Saturday May 17, 2025, 6 pm ATS International Conference:
Poster Title: Ligand-Independent TREM-1 Blockade Ameliorates Pulmonary Inflammation and Fibrosis
Presenter: Alexander B. Sigalov, Ph.D. (SignaBlok President and Principal Investigator)
Abstract Presentation Number: 9150
Session: A22 – Break on through: Airway epithelial barrier in inflammation and injury
Date / Time: Sunday May 18, 2025, 9:15 am – 11:15 am

About TREM-1
Triggering receptor expressed on myeloid cells 1 (TREM-1) serves as an inflammation amplifier. As such, TREM-1 is involved in the pathogenesis of sepsis, ARDS, PF, and other inflammatory pathologies. Clinical targeting of TREM-1 is challenging due to multiple known and still unidentified TREM-1 ligands.

About SignaBlok
SignaBlok, Inc. is a Massachusetts-based biotechnology company founded in 2009 to develop innovative, first-in-class therapeutics for targeted treatment of inflammation-associated diseases through the use of two key SignaBlok's proprietary technologies: 1) new mechanism-based approach to inhibition of cell receptors by using innovative, ligand-independent inhibitory peptides (the so-called SCHOOL peptides, the abbreviation coming from the "Signaling Chain HOmoOLigomerization" model of immune signaling); and 2) nature-inspired, multifunctional nanotechnology for targeted drug and/or imaging agent delivery to macrophages. Additional information about SignaBlok is available at www.signablok.com.